정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 597 | Recruiting | Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 | Covid19 | Drug: GX-I7 Drug: GX-I7 vehicle |
Phase 1 | Genexine, Inc. | INDUSTRY | 40 | All | 19 Years | Borame Medical Center, Seoul, Korea, Republic of |
| 596 | Recruiting | Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 | Covid19 | Biological: MesenCure | Phase 2 | BonusBio Group Ltd | INDUSTRY | 35 | All | 18 Years ~ 80 Years | Rambam Health campus, Haifa, Israel |
| 595 | Recruiting | Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) | SARS-CoV-2 Infection | Biological: ABNCoV2 Vaccine | Phase 1 | Radboud University, European Union | OTHER | 42 | All | 18 Years ~ 55 Years | Radboud univserity medical center, Nijmegen, Gelderland, Netherlands |
| 594 | Recruiting | Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 | Covid19 | Drug: Emricasan Other: Placebo |
Phase 1 | Histogen | INDUSTRY | 50 | All | 18 Years | SUNY Downstate Health Sciences University, Brooklyn, New York, United States |
| 593 | Recruiting | Safety and Tolerability of Single and Multiple Doses of Neumifil | Viral Respiratory Tract Infection | Drug: Neumifil Drug: Placebo |
Phase 1 | Pneumagen Ltd. | INDUSTRY | 60 | All | 18 Years ~ 60 Years | Hammersmith Medicines Research (HMR), London, United Kingdom |
| 592 | Recruiting | Safety and Tolerability Study of IV ST266 in COVID-19 Subjects | Cytokine Release Syndrome | Biological: ST266 | Phase 1 | Noveome Biotherapeutics, formerly Stemnion, IQVIA Biotech | INDUSTRY | 12 | All | 18 Years ~ 70 Years | Innovative Research of West Florida, Clearwater, Florida, United States Great Lakes Clinical Trials, Chicago, Illinois, United States WR-ClinSearch, LLC, Chattanooga, Tennessee, United States |
| 591 | Recruiting | Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19) | SARS-CoV-2 Infection | Biological: MT-2766 High dose Drug: Placebo Biological: MT-2766 Low dose |
Phase 2 | Medicago, Mitsubishi Tanabe Pharma Corporation | INDUSTRY | 145 | All | 20 Years | Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan Medical Corporation Heishinkai OCROM Clinic, Suita-shi, Osaka, Japan Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan |